MET and hepatocellular carcinoma: Other novel therapeutic targets for HCC include inhibitors of transforming growth factor (TGF)-β, c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor and fibroblast growth factor receptor 4 [114].